Compare CCAP & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCAP | DRTS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.2M | 607.1M |
| IPO Year | N/A | N/A |
| Metric | CCAP | DRTS |
|---|---|---|
| Price | $14.59 | $7.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $16.50 | $8.00 |
| AVG Volume (30 Days) | 253.8K | ★ 367.3K |
| Earning Date | 02-18-2026 | 11-20-2025 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $172,891,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.03 | $2.30 |
| 52 Week High | $20.19 | $7.89 |
| Indicator | CCAP | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 67.80 |
| Support Level | $14.28 | $6.45 |
| Resistance Level | $14.93 | $5.14 |
| Average True Range (ATR) | 0.34 | 0.54 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 63.73 | 75.64 |
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.